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Regenerative medicine offers the potential to treat and cure currently fatal and debilitating conditions through strategies such as the activation of de novo regenerative mechanisms or the in vitro development of tissues and organs for transplantation. The federal government has a long-standing interest in ensuring that the U.S. has the most effective and comprehensive regenerative medicine program in the world. Federal agencies are already involved in regenerative medicine research and in advancing the field of regenerative medicine together with academia and private industry. The U.S. Government Accountability Office (GAO) has released a timely and comprehensive report to congressional requestors on the federal activities that have an impact on the field of regenerative medicine. Federal investment, information sharing, and challenges of the field were presented. The report describes (a) which federal agencies conducted or funded regenerative medicine research in fiscal years 2012--2014, (b) the activities these federal agencies undertake to share information across agencies, and (c) the challenges to advancing the field of regenerative medicine identified by federal agencies and other stakeholders, and the steps taken, if any, to address them.

The study reviewed reports and other relevant documentation from federal agencies that have conducted or funded regenerative medicine research, including the strategic plan agendas and meeting minutes from the Multi-Agency Tissue Engineering Sciences Interagency Working Group (MATES), a forum including the National Institutes of Health (NIH), Department of Defense (DOD), Department of Veterans Affairs (VA), National Science Foundation (NSF), Food and Drug Administration (FDA), National Nuclear Security Administration (NNSA), and National Institute of Standards and Technology (NIST). The study also included interviews with federal agency officials and knowledgeable nonfederal stakeholders from academic and state-funded institutions, such as California Institute for Regenerative Medicine, University of Washington Institute for Stem Cells and Regenerative Medicine, and Wake Forest Institute for Regenerative Medicine. Contributors also included representatives from patient advocacy groups and trade organizations.

The findings of the report identified 7 government agencies that conducted or funded regenerative medicine research in fiscal years 2012 through 2014. In overall terms, funding is dominated by the NIH, which provided \$2.54 billion for regenerative medicine and accounting for 88% of the \$2.89 billion of federal expenditure on regenerative medicine identified by the authors. This \$2.54 billion resulted in approximately 2,400 awards per year, with largest investments of the NIH budget coming from the National Heart, Lung, and Blood Institute (24%), the National Institute of Diabetes and Digestive and Kidney Diseases (10%), and the National Cancer Institute (9%). After the NIH, the DOD is the second largest funder of regenerative medicine research, with investment of almost \$253 million, or about 9% of the total federal investment in regenerative medicine. This investment funded approximately 178 projects focused on the health needs of active-duty military personnel. Within the DOD, the Defense Health Program provided the largest investment (47%), followed by the Office of Naval Research (17%) and the U.S. Army (17%), which included investment in the Armed Forces Institute of Regenerative Medicine (AFIRM), which received \$42.66 million in funding for regenerative medicine research at U.S. academic institutions and private companies. The VA and NSF were the third and fourth largest funders of regenerative medicine research, respectively, investing \$40.95 million (VA) and \$40.23 million (NSF) over the analyzed time period. The remaining federal agencies (FDA, NNSA, and NIST) account for less than 1% of the total investment in regenerative medicine research. (More information is given in [supplemental online Table 1](http://stemcellstm.alphamedpress.org/lookup/suppl/doi:10.5966/sctm.2015-0280/-/DC1).)

The report also investigated the current mechanisms in place to facilitate information sharing of the regenerative medicine research funded or performed by these agencies. The report found that the established information-sharing mechanisms are effective and widely supported, given the broad range of disciplines and research missions represented by the agencies. Mechanisms include regular meetings of the MATES Interagency Working Group and collaborative ad hoc activities such as cofounding research and cosponsoring workshops. These joint workshops are opportunities for members to present and share information regarding research conducted or funded by their agencies, highlighting agency goals, specialties, and diverse approaches. Additional mechanisms for interagency collaboration include the cofunding of research, such as the NIH/NSF/NIST joint funding of the Enabling Technologies for Tissue Engineering and Regenerative Medicine program*,* and NIH/VA cofounded projects within DOD's AFIRM. The opinion of the federal stakeholders was that the decentralized approach to regenerative medicine funding fostered diversity of thought and priorities for advancing the field, allowing the research and science to proceed on multiple fronts simultaneously according to each agency\'s expertise but without the increased bureaucracy and slowed communication that a more formalized approach to information sharing and collaboration would require. Nonfederal stakeholders proposed that greater coordination of federal regenerative medicine activities could provide more focused attention and more rapid advancement in the field. In addition, there was support for the federal government providing a statement of commitment and a national strategy for regenerative medicine research as a means to enhance information sharing across agencies, ensure the research funding allocated to the field is used wisely, speed the development of new regenerative medicine products, and keep the U.S. at the forefront of innovations in this field.

The third task of the report was to evaluate the challenges facing the field of regenerative medicine and steps taken, if any, to address them. The report highlighted several main challenges identified by federal and nonfederal stakeholders. The main challenges identified were the lack of a systematic mechanism for federal agencies to collaborate with nonfederal entities, difficulties in recruiting and maintaining qualified scientists versed in regenerative medicine in federal agencies, difficulties in navigating the regulatory review process when seeking FDA approval of a new product, and the setting of payment policies and Medicare reimbursement mechanisms, processes, and rates for FDA-approved regenerative medicine products. Federal and nonfederal stakeholders offered potential strategies to address some of these challenges. It was proposed that convening a group of regenerative medicine stakeholders from across the federal government, industry, and academia to discuss progress in the field and opportunities for collaboration across stakeholder groups could help build stronger relationships and communication between federal and nonfederal stakeholders. Also, efforts to hold regenerative medicine meetings in Washington, D.C., could reduce travel costs and boost attendance, given the recent restrictions on travel to and attendance at scientific meetings for many federal agencies. To address the lack of qualified scientists with interdisciplinary training and experience in regenerative medicine research, many stakeholders supported the establishment of interdisciplinary postdoctoral fellowships such as those provided by NIH/NIST to allow scientists focused on regenerative medicine to work across agencies.

Stakeholders also emphasized that receiving FDA approval for regenerative medicine products can be challenging, as these products are often highly individualized treatments that do not conform to a single type of therapy. These stakeholders suggested that the characteristics of the current regulatory system may create a disincentive for product sponsors to bring regenerative medicine products to the market in the United States. Some stakeholders advocated for a separate FDA approval pathway for regenerative medicine products, noting they are different from drugs, as they are not typically distributed throughout the body, and different from devices. Interviewed participants also expressed concerns that the Centers for Medicare and Medicaid Services (CMS) is not planning sufficiently for the availability of future regenerative medicine products following FDA approval, citing the lack of CMS involvement in MATES and engagement in the field in general. While CMS does not take steps to proactively reach out to the regenerative medicine community, it welcomes product sponsors to contact CMS about the status of potential new products. Lessons may be learned in this area from the DOD, which has its own system for determining payment policies for the products that are covered by its TRICARE program. The DOD emphasized the importance of planning for coverage decisions for new treatments that do not have precedents for how to structure payments.

With federal expenditure on regenerative medicine totaling \$2.89 billion in fiscal years 2012--2014, the federal government has a major impact in advancing the field of regenerative medicine and in developing national strategies and priorities that help invigorate the field and encourage greater support for the research. This report highlighted these federal efforts and identified the current and future pathways that federal agencies are taking to ensure efficient communication and collaboration between federal and nonfederal entities, recruiting scientists versed in regenerative medicine, navigating the regulatory review and product approval process, and making decisions about Medicare coverage and reimbursement rates, mechanisms, and processes for newly approved products.

A report on the state of the regenerative medicine field is a monumental task. It is obvious from the final report that the GAO excelled in this task, not only defining the state of the field, but also accurately gauging its emerging impact. The full and abbreviated reports can be found through the following links:Highlights (html): <http://www.gao.gov/products/GAO-15-553>Highlights (pdf): <http://www.gao.gov/assets/680/670929.pdf>Full Report (pdf): <http://www.gao.gov/assets/680/670930.pdf>YouTube video: <http://www.youtube.com/watch?v=Pj8d9K9-ewk&autoplay=1&rel=0&showinfo=0>
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